Core Viewpoint - Xuan Bamboo Biotech-B (02575) has seen its stock price increase by nearly 70% since its listing, with a recent rise of over 9% following the announcement of clinical trial results for its drug, Pyrocilin, in treating HR+/HER2- advanced breast cancer [1][2] Group 1: Stock Performance - As of the latest update, Xuan Bamboo Biotech-B's stock price is reported at 49.28 HKD, with a trading volume of 12.67 million HKD [1] - The stock has experienced a cumulative increase of approximately 70% since its initial public offering [1] Group 2: Clinical Trial Results - On October 22, 2025, Xuan Bamboo Biotech-B announced the presentation of mid-term analysis results from the Phase III clinical trial (BRIGHT-3) at the 2025 European Society for Medical Oncology (ESMO) [1] - The mid-term data from the BRIGHT-3 study has led to the acceptance of a new drug application by the National Medical Products Administration of China for Pyrocilin in combination with aromatase inhibitors for HR+/HER2- advanced breast cancer [1] Group 3: Drug Approval and Mechanism - Pyrocilin (brand name: Xuan Yuening) is a novel CDK2/4/6 inhibitor that exhibits a unique multi-target synergistic mechanism, effectively inhibiting tumor cell proliferation while significantly reducing common hematological toxicities associated with traditional CDK4/6 inhibitors [2] - On May 13, 2025, Pyrocilin received approval from the National Medical Products Administration of China for use in patients with disease progression after prior endocrine therapy, making it the first and only CDK4/6 inhibitor approved for single-agent indication in China [2]
轩竹生物-B再涨超9% 吡洛西利治疗乳腺癌相关临床数据于2025年ESMO公布